By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalix Biotherapeutics, Inc. 

2 Snunit Street, Science Park
P.O. Box 455
Karmiel    21000  Israel
Phone: 972-4-988-9488 Fax: 972-4-988-9489


SEARCH JOBS








Company News
Protalix (PLX) To Hold Second Quarter 2017 Financial Results And Corporate Update Conference Call On August 9, 2017 7/31/2017 1:19:58 PM
Protalix (PLX) Completes Private Note Exchange Of $9 Million Notes Maturing September 2018 For $8.55 Million Notes Maturing February 2022 7/26/2017 11:08:28 AM
Protalix (PLX) Announces Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis Presented At The 40th European Cystic Fibrosis Society Conference 6/7/2017 8:24:49 AM
Protalix (PLX) Announces Presentation Of Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis At The 40th European Cystic Fibrosis Society Conference 5/23/2017 11:12:54 AM
Protalix (PLX) Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease 5/9/2017 10:35:23 AM
Protalix (PLX) Announces New Preclinical Results Demonstrating A Positive Effect Of Pegunigalsidase Alfa (PRX-102) On Small-Fiber Neuropathy In Fabry Disease Models Compared To Commercially Available Enzyme Replacement Therapies 4/18/2017 11:03:19 AM
Protalix (PLX) Announces Private Note Exchanges And Private Placement Of Secured Convertible Notes Due 2021 12/2/2016 7:14:58 AM
Protalix (PLX) To Present At The Jefferies 2016 Global Healthcare Conference 6/2/2016 10:24:34 AM
Protalix (PLX) Sells Back ELELYSO Rights to Pfizer (PFE) for $46 Million 10/13/2015 6:40:43 AM
Protalix Biotherapeutics, Inc. (PLX) To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF 10/5/2015 7:26:18 AM
12345678910...
//-->